ALXN - AstraZeneca's acquisition of Alexion cleared in Europe

Roland Magnusson/iStock Editorial via Getty Images AstraZeneca (AZN) has received the clearance from the European Commission for its proposed acquisition of rare disease specialist Alexion Pharmaceuticals (ALXN). The deal valued at $39B was previously cleared in the U.S., Japan, and several other countries. The competition clearance from the U.K. is pending, the company said in a statement. On May 11, the shareholders of both companies have approved the acquisition following which a group focused on rare diseases will be created. The unit named ‘Alexion, AstraZeneca Rare Disease’ will be based on Boston, Massachusetts. “We are now another step closer to closing the acquisition and combining the two companies to create a leader in immunology and precision medicines. We continue to progress towards the completion of the acquisition during this quarter," commented Marc Dunoyer AstraZeneca CFO. AstraZeneca is not concerned about potential competition concerns in the U.K. that could derail its

For further details see:

AstraZeneca’s acquisition of Alexion cleared in Europe